Andrei-Mihai Vasilescu, PhD Student

Andrei-Mihai Vasilescu
Group: Enzymology
Department: Enzymology

Research Assistant

Biography

Andrei-Mihai Vasilescu is a researcher in the Institute of Biochemistry of the Romanian Academy. Andrei-Mihai is currently working in Enzymology in the Enzymology.

Papers

Year
  • Adina-Gabriela Vasilescu, Andrei-Mihai Vasilescu, Livia Elena Sima, Natalia Baran, Ștefan-Eugen SzedlacsekAdina-Gabriela Vasilescu et al . ""Breaking the cancer code: a novel DNA minicircle to disable STAT3 in ovarian cancer cells SKOV3"", Frontiers in Pharmacology 16(Article number: 1673427): 1 - 15, (2025)
    doi: 10.3389/fphar.2025.1673427
    IF: 4.80AI: 1.02
  • Andrei-Mihai Vasilescu, Adina-Gabriela Vasilescu, Livia Elena Sima, Cristian V.A. Munteanu, Natalia Baran, Stefan-Eugen SzedlacsekAndrei-Mihai Vasilescu et al . ""A novel cytotoxic anti-B7-H3 affibody with therapeutic potential in acute myeloid leukemia"", Frontiers in Pharmacology 16(Article number 1684226): 1 - 13, (2025)
    doi: 10.3389/fphar.2025.1684226
    IF: 4.80AI: 1.02

Grants

Novel radiolabeled affibodies for targeted imaging and therapy 2019-2022
Acronym: Bilateral agreement no.3698/13.09.2018 Romanian Academy- Hungarian Academy of Sciences
Project director: Stefan Szedlacsek

The project is agreed as a bilateral collaboration between IBAR and ATOMKI, and the University of Debrecen and IFIN-HH participate in this project voluntarily.

Radiolabelling of affibody for tumor diagnostic and theranostic application in the nuclear medicine 2022-2024
Acronym: Bilateral agreement no.2886/15.09.2021 Romanian Academy- Hungarian Academy of Sciences
Project director: Stefan Szedlacsek

The project is agreed as a joint collaboration among IBAR, ATOMKI and UD, the latter being a cost free participant. There are two main directions envisaged by the proposed project: - receptors mapping and therapy, using an affibody against HER2 receptors, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establishing labelling procedures; c) ex vivo and/or in vivo testing of optimal compounds.